Terazosin

Terazosin

Clinical data
Trade names	Hytrin
Other names	[4-(4-amino-6,7-dimethoxy-quinazolin-2-yl)piperazin-1-yl]-tetrahydrofuran-2-yl-methanone
AHFS/Drugs.com	Monograph
MedlinePlus	a693046
ATC code	G04CA03 (WHO)
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Protein binding	90-94%
Elimination half-life	12 hours
Identifiers
IUPAC name (RS)-6,7-dimethoxy-2-[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]quinazolin-4-amine
CAS Number	63590-64-7 Y
PubChem CID	5401
DrugBank	DB01162 Y
ChemSpider	5208 Y
UNII	8L5014XET7
KEGG	D08569 Y
ChEBI	CHEBI:9445 Y
ChEMBL	ChEMBL611 Y
CompTox Dashboard (EPA)	DTXSID3023639
ECHA InfoCard	100.118.191
Chemical and physical data
Formula	C19H25N5O4
Molar mass	387.433 g/mol g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C(N3CCN(c2nc1cc(OC)c(OC)cc1c(n2)N)CC3)C4OCCC4
InChI InChI=1S/C19H25N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22) Y Key:VCKUSRYTPJJLNI-UHFFFAOYSA-N Y
(verify)

Terazosin (marketed as Hytrin or Zayasel) is a selective alpha 1 antagonist used for treatment of symptoms of an enlarged prostate (BPH). It also acts to lower the blood pressure, and is therefore a drug of choice for men with hypertension and prostate enlargement.

It works by blocking the action of adrenaline on smooth muscle of the bladder and the blood vessel walls.

Most common side effects include dizziness, drowsiness, headache, constipation, loss of appetite, fatigue, nasal congestion or dry eyes, but they generally go away after only a few days of use. Therapy should always be started with a low dose to avoid first dose phenomenon. Sexual side effects are rare, but may include priapism or erectile dysfunction.